<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01167309</url>
  </required_header>
  <id_info>
    <org_study_id>LEO 27847-S02</org_study_id>
    <nct_id>NCT01167309</nct_id>
  </id_info>
  <brief_title>LEO 27847 - Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in Secondary Hyperparathyroidism Patients</brief_title>
  <official_title>LEO 27847 - Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in Secondary Hyperparathyroidism Patients With Chronic Kidney Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LEO Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LEO Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to determine the safety and tolerability of ascending single and
      multiple oral doses of LEO 27847 in secondary hyperparathyroidism patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability</measure>
    <time_frame>7 days after last dosing</time_frame>
    <description>Adverse events, vital signs, ECG, laboratory evaluation, physical examination</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics and Pharmacodynamics</measure>
    <time_frame>7 days after last dosing</time_frame>
    <description>LEO 27847, PTH, calcium, Vitamin D and phosphate in blood. LEO 27847 in urine</description>
  </secondary_outcome>
  <enrollment type="Actual">72</enrollment>
  <condition>Secondary Hyperparathyroidism</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LEO 27847</intervention_name>
    <description>First in patient</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged 18 to 75 years (inclusive) at screening.

          -  Patients with body mass index within 18 to 34 kg/m2 (inclusive).

          -  Haemoglobin is stable (≥9 g/dL or 5.6 mmol/L)

          -  Parathyroid hormone (PTH) is ≥200 pg/mL and &lt;800 pg/mL.

          -  Screening serum albumin is ≥30 g/L.

          -  C-reactive protein &lt;25 mg/L.

        Exclusion Criteria:

          -  Adjustment of vitamin D sterols within 14 days before the screening visit and patients
             for whom adjustment of vitamin D sterols is planned from screening until end of study.

          -  Adjustment of calcium supplements within 14 days before the screening visit and
             patients for whom adjustment of calcium supplements is planned from screening until
             end of study.

          -  Adjustment of phosphate binder within 14 days before the screening visit and patients
             or whom adjustment of phosphate binder is planned from screening until end of study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Atef Halabi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CRS Clinical Research Services Kiel GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CRS Clinical Research Services Kiel GmbH</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centralny Szpital Kliniczny MON</name>
      <address>
        <city>Warszawa</city>
        <zip>04-141</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Poland</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 2, 2010</study_first_submitted>
  <study_first_submitted_qc>July 20, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2010</study_first_posted>
  <last_update_submitted>January 20, 2012</last_update_submitted>
  <last_update_submitted_qc>January 20, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 23, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Safety and tolerability of LEO 27847</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Hyperparathyroidism</mesh_term>
    <mesh_term>Hyperparathyroidism, Secondary</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

